Evolving Anti-Aβ Therapeutics: From Plaque Clearance to Precision Delivery

Over the past decade, the development of new drugs for Alzheimer's disease (AD) has encountered repeated setbacks. However, in recent years, monoclonal antibodies targeting amyloid-β (Aβ) have demonstrated the ability to reduce plaque load in the brain in large-scale clinical trials and shown a trend towards slowing cognitive decline in some patients with early-stage disease, marking a substantive step forward in the clinical validation of the anti-Aβ therapeutic strategy.

At the 2025 Clinical Trials on Alzheimer's Disease (CTAD) conference, the focus of related discussions has gradually shifted from the question of "whether this strategy is effective" to deeper issues: how to systematically enhance the safety and implementation efficiency of the treatment based on the established efficacy, to better meet the needs of long-term clinical practice.

Plaque Removal Achieves Breakthroughs, but Safety Remains a Key Challenge

Multiple clinical studies have demonstrated that sustained reduction of cerebral Aβ levels can slow disease progression in some patients, laying the foundation for the clinical application of AD-related drugs. However, numerous presentations at CTAD 2025 pointed out that current anti-Aβ therapies still face significant real-world challenges, particularly amyloid-related imaging abnormalities (ARIA), which include cerebral edema (ARIA-E) and microhemorrhages (ARIA-H). The occurrence of ARIA not only influences the dosing selection and administration strategies of antibodies but also significantly increases the complexity of radiographic monitoring and clinical management. Consequently, as the efficacy of anti-Aβ strategies is gradually validated, the field is entering a new research phase: determining how to better balance safety and therapeutic benefits while maintaining plaque clearance capability has become a core issue urgently requiring resolution.

MRI Comparison Between a Healthy Brain and a Brain with ARIA-E and ARIA-H

BBB Shuttle Technology: Optimizing Delivery Pathways as a Novel Strategy to Mitigate ARIA Risk

Traditional anti-Aβ monoclonal antibodies primarily rely on passive diffusion to enter the central nervous system. To achieve sufficient brain exposure and plaque-clearing efficacy, high peripheral dosing is often required, which can contribute to an increased risk of ARIA. In recent years, blood-brain barrier (BBB) shuttle technology has gained significant attention. Particularly, mechanisms leveraging transferrin receptor (TfR)-mediated transcytosis offer a novel pathway for antibody delivery. By engineering antibody molecules with optimized BBB shuttle modules, it is possible to enhance distribution efficiency within the brain parenchyma without substantially increasing systemic exposure.

Current research indicates that such BBB-shuttled antibodies achieve higher brain exposure while demonstrating relatively lower binding to cerebrovascular amyloid angiopathy (CAA) compared to conventional antibodies. This distribution profile—favoring parenchymal delivery over vascular binding—is theorized to help reduce vessel-related injury, thereby potentially lowering the risk of ARIA.

Schematic Diagram of Antibody Delivery to Brain Parenchyma via BBB Shuttle Technology

Research Progress and Pipeline Landscape: Delivery Pathways Emerge as a Key Focus

At the CTAD 2025 conference, data presented by Dr. Ronald DeMattos from Eli Lilly compared Trontinemab—a next-generation antibody based on gantenerumab and fused with a TfR shuttle module—against conventional gantenerumab. The data revealed that Trontinemab achieved a higher rate of plaque clearance within a relatively shorter treatment period. Furthermore, within the disclosed data range, the incidence of ARIA-E associated with Trontinemab was lower than historically reported rates for conventional gantenerumab studies, overall presenting a more promising benefit-risk profile.

Currently, multiple pharmaceutical companies globally are actively developing next-generation anti-Aβ antibody pipelines, exploring various BBB shuttle technology platforms including TfR, CD98, and INSR. Delivery pathways and in vivo distribution characteristics are increasingly becoming important considerations in the differentiated design of anti-Aβ therapies.

Pipeline of Anti-Aβ Antibody Drug Development

Conclusion

Overall, the key message from CTAD 2025 is clear: the research focus of anti-Aβ therapeutics is progressively shifting from "plaque removal" towards "optimizing delivery pathways and in vivo distribution". BBB shuttle technology offers a promising new direction for improving brain delivery efficiency and exploring the potential to reduce ARIA risk, and it is already influencing the design strategies for the next generation of anti-Aβ antibodies. Future differentiation and competition in this field will likely depend more on achieving a superior balance between efficacy and safety.

Innovative Solutions from ACROBiosystems: Driving Progress in AD Research

As the brand focused on neuroscience of ACROBiosystems, Aneuro offers cutting-edge solutions, including target proteins, pre-formed fibrils (PFFs), stable cell lines, and p-tau antibodies, to accelerate AD research and drug development.

Learn More About AD Related Proteins

References